Figure 7From: Phase II clinical trial of whole-brain irradiation plus three-dimensional conformal boost with concurrent topotecan for brain metastases from lung cancer For non-small cell lung cancer, the MST and the 1- and 2-year survival rates of the two groups were 10Â months, 33.8%, 16.9% and 8Â months, 26.3%, 9.9%, respectively. Back to article page